UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow.

Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance GSK reported core earnings of $1.09 per American depositary share (ADS) for second-quarter 2024, beating the Zacks Consensus Estimate of $1.00.

Written by Zacks Equity Research for Zacks -> A month has gone by since the last earnings report for GSK (GSK). Shares have lost about 6.6% in that time frame, underperforming the S&P 500.

GSK will be part of the research on safety, efficacy and manufacturing scalability, but, eventually, it would be ideal for a third party to come in and take the product further, she added.

Avandia: GlaxoSmithKline Cover-Up Turns Off Doctors GlaxoSmithKline withheld studies that made their drug Avandia, look unsafe. By ABC News July 13, 2010, 11:24 AM ...